Our article on SPECT/CT published on July 7, 2005 incorrectly stated that Boston Life Sciences had submitted and was awaiting approval for a new drug application (NDA) to the Food and Drug Administration for its I-123 Altropane radiopharmaceutical.
Although the company completed a phase III trial for Altropane, it has not yet submitted an NDA. It is now conducting a second phase III trial under a special protocol assessment (SPA) with the FDA to determine the agent's potential use in differentiating Parkinsonian from non-Parkinsonian tremors.
In addition, it was incorrectly stated that a match in nuclear ventilation/perfusion (V/Q) scan is considered suspicious of a pulmonary embolism. This should have read that a mismatch is considered suspicious of PE.
You can read the corrected article by clicking here.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
